Chk1 is essential in maintaining genomic stability due to its role in cell cycle regulation. Several recent studies have indicated that the abrogation of checkpoints in tumourigenesis through the inhibition of Chk1 may be of therapeutic value. To further investigate the role of Chk1 in the mouse small intestine and its potential role as a therapy for colorectal cancer, we simultaneously deleted Chk1 and Apc in the mouse small intestine. We found that homozygous loss of Chk1 is not compatible with Wnt-driven proliferation and resulted in the suppression of Wnt-driven tumourigenesis in the mouse small intestine. In contrast, heterozygous loss of Chk1 in a Wnt-driven background resulted in an increase in DNA damage and apoptosis and accelerated both tumour development and progression.
INTRODUCTION
Genomic instability appears to be a crucial feature in tumour development and is thought to be one of the key characteristics of late-stage colon cancer. 1 The loss of genomic stability in tumour progression through DNA damage, tumour-specific DNA repair defects and the loss of cell cycle checkpoints has been proposed to create a permissive environment for potential changes in both oncogenes and tumour-suppressor genes. The accumulation of these genetic and epigenetic alterations is thought to lead to the transformation of normal colon epithelial cells to colon adenocarcinoma cells, resulting in the stepwise development of colorectal cancer. 2 In addition to driving the disease, the genomic instability of tumours also provides therapeutic opportunities, and the exploitation of the reliance of cancer cells on the DNA damage response pathways has been shown to be a valid therapeutic strategy. [3] [4] [5] [6] The ATR-Chk1 checkpoint pathway is a key DNA damage response pathway that has been shown to be an important barrier to the progression of pre-neoplastic lesions and has the potential to be used as a synthetic lethal target in tumourigenesis. [7] [8] [9] Chk1 is a serine/threonine protein kinase that is active at the intra-Sphase, G2/M and the spindle checkpoints of the cell cycle and is therefore a key factor in maintaining genomic stability. 10 Several recent studies have indicated that the abrogation of these checkpoints through the inhibition of Chk1 may be of therapeutic value, as the loss of the G2/M checkpoint causes the sensitization of tumour cells that are defective in the G1 checkpoint to DNA-damaging agents and results in the redirection of tumour cells to apoptotic pathways. 4, 6, 11 Homozygous loss of murine Chk1 is embryonically lethal 12 and tissue-specific deletion of Chk1 results in extensive cell death in proliferating tissues but has been shown to be tolerated in quiescent tissues such as the liver. [13] [14] [15] This increase in apoptosis in proliferative cells due to Chk1 deletion has been associated with genomic instability and p53 accumulation, although this apoptotic phenotype has been shown to be p53-independent by several studies. [14] [15] [16] Chk1 heterozygosity has also been shown to result in checkpoint disruption, genomic instability and enhanced tumourigenesis in specific tissues implicating it as a tumour suppressor. 13, 17 Recent work has also confirmed the potential role of Chk1 as a feasible cancer-cell-specific therapy as Tho et al. 17 demonstrated that Chk1 is indispensable for the formation of chemical-induced skin tumours.
We have previously used a conditional model to investigate the consequences of Chk1 loss in the murine small intestine. 11 These studies showed that homozygous loss of Chk1 resulted in the ablation of the Chk1 null epithelium and subsequent repopulation by wild-type cells. However, we did not observe an atypical phenotype in the Chk1 heterozygous epithelium. We have now extended these studies to determine the effect of Chk1 loss in the context of activated Wnt signalling. First, as might be predicted from previous studies, we show that the complete loss of Chk1 is able to suppress Wnt-driven proliferation and tumourigenesis, although Chk1 haploinsufficiency promotes Wnt-driven tumourigenesis.
RESULTS
Homozygous loss of Chk1 suppresses Wnt-driven proliferation in the mouse small intestine In order to investigate the effect of Chk1 loss on the Apc phenotype, Chk1 mice carrying the loxP-flanked Chk1 allele were crossed onto the conditional Apc background. 18, 19 Cre activity was induced in experimental (AhCre ) and control mice (AhCre 
Chk fl/fl mice, both experimental and control cohorts were killed at day 2 and day 4 time points post-induction (PI).
In order to assess the phenotypic consequences of the conditional deletion of both Chk1 and Apc, we analysed the crypt À villus structure. Histological sections from day 2 PI revealed the previously characterized apoptotic phenotype of Chk1 loss in the mouse small intestine in the Chk1 homozygous mice (AhCre Chk fl/ þ mice as the previously characterized 'crypt progenitor-like' phenotype of Apc loss in the mouse small intestine does not occur until day 4 PI, 21 whereas, at day 4 PI (Figure 1a) , both of these cohorts demonstrated an increase in crypt cell proliferation and perturbed migration, consistent with previous studies. 21 The phenotype of the AhCre þ Apc þ / þ Chk fl/fl control mice at day 4 PI was also consistent with our previous studies, whereby Chk1 loss resulted in widespread apoptosis, crypt death and subsequent crypt repopulation (Figure 1a ). From the histological sections shown (Figure 1a ), both crypt death and repopulation of crypts can be observed at day 4 PI in both the control AhCre (Figure 1b) , although some heterogeneity with respect to the protein levels were seen (Supplementary Figure 2) , which may be due to a variation in the repopulation levels within this cohort.
To quantify the phenotypic changes indicated by the histological analysis, the number of live crypts and cells per crypt were scored from the haematoxylin and eosin-stained sections as described previously. 22 Dying crypts were characterized by a high level of apoptosis and loss of the crypt À villus structure, whereas live crypts consisted of low level apoptosis, a normal crypt À villus structure and demonstrated cell proliferation. The data for the control mice (AhCre Figure 2a ) at day 4 PI were consistent with previous data, 14, 18, 21 with a significant decrease in crypt survival for the AhCre þ Apc þ / þ Chk fl/fl mice compared with wild type (n ¼ 4, Mann-Whitney U-test P ¼ 0.0259) and no significant change between the wild type and AhCre þ Apc
Similar to the observations from the histological analysis, the loss of a single Chk1 allele had no effect on the Apc homozygous phenotype with respect to crypt survival (n ¼ 3, Mann-Whitney U-test P ¼ 1.00), whereas homozygous loss of Chk1 in combination with Apc deletion (AhCre To determine whether there were any differences in cellularity within the live crypt population, the number of cells per crypt was scored ( Figure 2b ). Similar to the crypt survival results, the data for the control mice at day 4 PI (AhCre 
Loss of a single Chk1 allele had no effect on crypt cellularity of the Apc homozygous mice (Figure 2b ;
, although homozygous loss of Chk1 did result in a significant decrease in crypt cell number (n ¼ 7, Mann-Whitney U test P ¼ 0.0259), confirming that Chk1 loss in combination with Apc loss results in the attenuation of the Apc phenotype.
In order to further assess the effect of the simultaneous loss of Chk1 and Apc on the Apc phenotype and also to confirm the loss of Apc, we carried out immunohistochemical analysis of b-catenin. Nuclear relocalization of b-catenin, as a result of dysregulated Wnt signalling, is a widely used surrogate marker of Apc loss. Immunohistochemical analysis confirmed Apc loss in our AhCre Dying crypts appear to have nuclear b-catenin, whereas the live crypts appear to have cytoplasmic or membrane-associated b-catenin, demonstrating that, after crypt death due to the loss of Chk1, crypt repopulation occurs with wild-type Apc-expressing cells.
Chk1 heterozygosity results in a haploinsufficient phenotype when Apc is also lost In addition to quantifying crypt survival and cell number, apoptosis and mitosis were quantified as described previously. 17 The data for the control mice (AhCre (Figures 3a and b) . Chk1 deletion also resulted in a significant further increase in apoptosis in the Figures 3a-c) . Notably, although the heterozygous loss of Chk1 had no effect at day 2 PI (Supplementary Figure 1b) , at day 4 PI, the loss of the single Chk1 allele in combination with the homozygous loss of Apc resulted in a significant increase in apoptosis (AhCre þ Apc Figure 3a) .
The above observations show that, in addition to the homozygous loss of Chk1 having a significant effect on the Apc phenotype in the mouse small intestine, conditional heterozygous loss of Chk1 in the context of Apc deficiency elevates cell death. To further investigate whether this increase in apoptosis was due to Chk1 heterozygosity promoting DNA damage, immunohistochemical analysis was carried out for phospho-H2A.X, an established DNA-damage marker that becomes phosphorylated and activated in the presence of DNA damage. 23, 24 Conditional
Chk1 loss and Wnt-driven intestinal tumorigenesis KR Greenow et al homozygous loss of Chk1 resulted in an increase in phospho-H2A.X (Figure 3d ), indicating an increase in DNA damage. Mice homozygous for Apc loss (AhCre þ Apc fl/fl Chk þ / þ ) also showed an increase in H2A.X staining, which was further increased by the loss of a single Chk1 allele. This increase in phospho-H2A.X staining was quantified and confirmed a significant increase in phospho- ) and control mice (AhCre ) and control mice (AhCre Loss of Chk1 modifies Wnt-driven tumourigenesis From the above short-term data, it is clear that the loss of Chk1 has a significant impact on Wnt-driven proliferation, which could potentially perturb Wnt-driven tumourigenesis. In order to test this hypothesis, we crossed the loxP-flanked Chk1 onto a conditional Apc heterozygous background, a well-established colorectal cancer model. 19 Cre activity was induced in both
by three intraperitoneal injections of 80 mg/kg b-naphthoflavone in 24 h. We induced cohorts of more than 15 experimental and control mice and allowed them to age. The mice were monitored regularly for signs of intestinal tumours (rectal bleeding, prolapse and anaemia) or other illness and were killed when they became symptomatic of disease.
As shown in Figure 4a , loss of either a single or both Chk1 alleles had a significant effect on survival. The Chk1 heterozygous (AhCre þ Apc fl/ þ Chk fl/ þ ) mice had a significantly reduced median ) and control mice (AhCre ) had a significantly increased median survival of 665 days (n ¼ 23, Mann-Whitney U-test, P ¼ 0.0013). All cohorts developed polyp-like lesions within the small intestine and the large intestine, and, although no significant difference was seen in the number of adenomas in the small intestine between either experimental cohort (AhCre (Mann-Whitney U-test, P ¼ 0.015; Figure 4b ). In addition, tumour size was measured, although no significant difference was seen between our experimental and control cohorts in either the small intestine or the large intestine. Intestinal tumour burden was also assessed ( Figure 4d ) and a significant reduction was seen in the large intestine ) and control mice (AhCre ) and control mice (AhCre
Chk þ / þ ) at day 4 PI. Tissue sections stained with antibodies detecting phosphorylated-H2A.X. Bar, 50 mm. We classified the lesions into microadenomas (T1) and adenomas that were confined to the mucosa (T2), early invasive adenocarcinomas showing invasion into the submucosa but not the muscularis propria (T3) and advanced invasive adenocarcinoma that penetrated into or through the muscularis propria (T4). From our observations, the control (AhCre þ Apc fl/ þ Chk þ / þ ) mice analysed had either benign microadenomas (44.4%), adenomas (100%) confined to the submucosa or adenocarcinomas (66.7%); however, only 11.1% had tumours invading into the muscularis propria (Figure 5b ). In contrast, 76.9% of the AhCre þ Apc fl/ þ Chk fl/ þ mice had muscle-invading adenocarcinomas in which the tumours had penetrated the muscularis propria to reach the serosa or subserosa, sometimes with the loss of differentiation, features that were never seen in the control mice. These data therefore demonstrate that the loss of a single Chk1 allele enhances tumour progression.
DISCUSSION
Human tumours frequently have defects in the maintenance of genomic integrity, which involves a loss of DNA damage response pathways and checkpoints, which causes cancer cells to be more reliant on intact cell cycle checkpoints and DNA repair pathways. This reliance can provide an opportunity for therapeutic intervention, and it may be possible to target tumour cells specifically, with limited toxicity, in normal tissue. The success of this strategy is illustrated by the progress of Chk1 inhibitors in early-phase clinical trials. 6 Although Chk1 inhibition does appear to be a promising strategy in cancer therapy and several studies have shown that Chk1 inhibition enhances tumour cell death, 17,25 a potential haploinsufficient role for Chk1 has also been shown 12, 13, [15] [16] [17] indicating that further studies are required to fully understand the use of Chk1 inhibition as a cancer therapy.
We have previously deleted Chk1 in the mouse small intestine and have demonstrated that, although the homozygous loss of this checkpoint protein has a highly traumatic, albeit transient effect, the heterozygous loss of Chk1 is well tolerated. 14, 25 In order to further investigate the potential use of Chk1 inhibition in cancer therapy, particularly in colorectal cancer, we used an early-stage Wntactivated model to characterize the effect of Chk1 deletion on the initial stages of aberrant Wnt signalling in the mouse small intestine.
The study presented in this paper clearly shows that the homozygous deletion of Chk1 in the mouse small intestine in combination with Apc prevents Wnt-driven proliferation, one of the key events in colorectal cancer. Our short-term studies demonstrated that the loss of both Chk1 alleles in the Apc homozygous mouse resulted in widespread apoptosis and crypt death and subsequent repopulation of the intestine with wildtype cells positive for Apc and Chk1. These results are in accordance with previous studies whereby Chk1 has been shown to be essential for the viability of proliferating cells due to its key role in cell cycle regulation. [13] [14] [15] In addition, our short-term studies demonstrate that Chk1 has a haploinsufficient phenotype when lost in a Wnt-driven environment. Heterozygous loss of Chk1 in combination with Apc resulted in an increase in apoptosis and DNA damage. Our previous studies have demonstrated that the loss of a single Chk1 allele in the mouse small intestine has no gross effect, and therefore this difference may be partly due to the crypt progenitor-like phenotype of Apc deletion in the mouse small intestine. Loss of Apc results in a decrease in the number of terminally differentiated cells, an increase in proliferation and ) showed a significant difference in lifespan when compared with the control cohort (AhCre
Formalin-fixed tissue was used to quantify tumour number, size and burden. The quartered circle symbol denotes the mean value.
Chk1 loss and Wnt-driven intestinal tumorigenesis KR Greenow et al endogenous DNA damage, and the intestine may be less resilient to the Chk1 heterozygosity, which is consistent with previous studies demonstrating that the loss of a single allele of key components of the DNA damage response pathway becomes critical under conditions of increased endogenous DNA damage in pre-malignant lesions, a theory described by Bartek et al. 9 as 'conditional haploinsufficiency'.
In addition to our short-term studies, we used the Apc heterozygous tumour model to assess the effect of Chk1 loss on tumourigenesis in the mouse intestine. A recent study by Tho et al. 17 has demonstrated that Chk1 deletion suppresses mouse skin tumourigenesis, although Chk1 heterozygosity resulted in tumour progression. We show that both heterozygous and homozygous deletion of Chk1 resulted in a significant effect on Wnt-driven tumourigenesis. Homozygous loss of Chk1 resulted in an increase in survival and a decrease in tumour number in the large intestine. This decrease in Wnt-driven tumourigenesis may be due to the ability of Chk1 loss to suppress Wnt-driven proliferation through apoptosis, crypt death and the repopulation of the intestine with wild-type Apc, eliminating Apc-deficient cells from the tissue. Although the homozygous loss of Chk1 did not completely suppress tumorigenesis and no difference was seen in tumour burden in the small intestine at time of death, it is important to note that tumorigenesis was slowed as Chk1 homozygous mice survived 50% longer than control Chk1 wild-type mice. This inability to completely suppress Wnt-driven tumourigenesis may be explained by floxing inefficiency of Chk1 resulting in the survival of some Apc-homozygous cells and also may be due to spontaneous secondary mutations in this tumour-permissive environment.
In contrast, Chk1 heterozygosity resulted in a significant decrease in survival compared with Chk1 wild-type mice. No increase in tumour number or size was seen, although, consistent with previous studies, 17 loss of a single Chk1 allele resulted in enhanced tumourigenesis with over a 60% increase in the number of mice developing advanced invasive adenocarcinomas compared with controls. This enhanced tumourigenesis may be due to an increase in genomic instability due to the loss of Chk1, as was suggested by the increase in DNA damage observed in our short-term studies. This increased susceptibility to tumour progression by heterozygous defects in components of DNA damage response pathways has been shown by previous studies and is thought to be due to the combination of the DNA-damage threshold being exceeded and the loss of cell cycle checkpoints, both of which facilitate tumour progression. 9, 11 In addition, the impairment in Chk1 function could also increase the probability of additional genetic changes; for example, it is known that the progression of the intestinal tumourigenesis is associated with mutation of additional genes such as Ras, 26 although analysis of our tumours showed this not to be the case in this study (data not shown).
Our observations here are consistent with previous studies whereby the deletion of Chk1 suppresses tumourigenesis. 17 This dependence is currently being exploited in the treatment of tumours through the use of Chk1 inhibitors. Although the complete loss of Chk1 appears to reduce tumourigenesis, both our results and previous studies demonstrate that Chk1 heterozygosity results in spontaneous DNA damage and an increase in tumourigenesis within specific tissues. 13, [15] [16] [17] Therefore, Chk1 clearly has a gene-dosage effect, a concept which has been shown for other components of the DNA damage response pathway, 9, 11 indicating that, although complete deletion of Chk1 may be a successful cancer therapy, the level of Chk1 inhibition is critical and further studies are required to fully understand the effect Chk1 haploinsufficiency. 
MATERIALS AND METHODS

Experimental mice
All procedures were conducted according to the UK Home Office regulations. Mice carrying the floxed Chk1 allele were kindly supplied by Dr Stephen J. Elledge 13 and all mice were maintained on an outbred background. Experimental mice were genotyped as previously described for the targeted Chk1 allele, 13 the targeted Apc allele, 19 the Rosa26R allele 27 and the AhCre transgene. 20 Cre activity was induced in control and experimental mice by three consecutive intraperitoneal injections of 80 mg/kg b-naphthoflavone (Sigma, Dorset, UK) within 24 h. In addition, selected animals were injected with 100 mg/kg Bromo-deoxyuridine (Sigma) and culled at indicated time points after labelling.
Histology and immunohistochemistry
Intestinal tissue was fixed in ice-cold 10% neutral-buffered formalin for no longer than 24 h before being processed into paraffin blocks according to standard procedures. Tissue sections (5 mm) were either stained using haematoxylin and eosin for histological analysis or were used for immunohistochemical analysis. The following antibodies were used for immunhistochemistry: anti-Caspase 3 (1:750; R&D Systems, Abingdon, UK), mouse anti-H2A.X (Ser139) (1:200, Millipore, Billerica, MA, USA), anti-bcatenin (1/50; Becton Dickinson, Oxford, UK) and mouse anti-BrdU (1:100; Becton Dickinson).
Western blot analysis
Protein was isolated from either intestinal epithelial-enriched pellets 28 or polyps isolated from experimental mice, and subsequent protein analysis, SDS À PAGE and western blotting were carried out following standard protocols. The Chk1 mouse monoclonal antibody (Abgent, Oxfordshire, UK) was used at 1:1000 and the mouse monoclonal b actin (Sigma) was used at 1:12000, and the appropriate horseradish peroxidase-conjugated secondary antibodies (GE Healthcare, Buckinghamshire, UK) were used at 1:3000. Densitometry was carried out using Image J software (v1.46 d).
